Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

ABSTRACT:

Introduction

The second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced ALK-rearranged NSCLC, establishing alectinib as the new standard first-line therapy. Brigatinib, another second-generation ALK inhibitor, has shown substantial activity in patients with crizotinib-refractory ALK-positive NSCLC; however, its activity in the alectinib-refractory setting is unknown.

Methods

A multicenter, retrospective study was performed at three institutions. Patients were eligible if they had advanced, alectinib-refractory ALK-positive NSCLC and were treated with brigatinib. Medical records were reviewed to determine clinical outcomes.

Results

Twenty-two patients

SUBMITTER: Lin JJ 

PROVIDER: S-EPMC6341982 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature